L-tryptophan | 1292840-51-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: L-tryptophan
• 英文别名: Trp-OMe；(3S)-3-amino-4-(1H-indol-3-yl)butan-2-one
• CAS: 1292840-51-7
• 化学式: C₁₂H₁₄N₂O
• 分子量: 202.256
• InChiKey: ZBABTBQHPLFKNK-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  58.9
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  L-tryptophan 、 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  3,4-Diaminobenzoic Acid Derivatives as Inhibitors of the Oxytocinase Subfamily of M1 Aminopeptidases with Immune-Regulating Properties

  摘要：

  Members of the oxytocinase subfamily of M1 aminopeptidases (ERAP1, ERAP2, and IRAP) play important roles in both the adaptive and innate human immune responses. Their enzymatic activity can contribute to the pathogenesis of several major human diseases ranging from viral and parasitic infections to autoimmunity and cancer. We have previously demonstrated that diaminobenzoic acid derivatives show promise as selective inhibitors for this group of aminopeptidases. In this study, we have thoroughly explored a series of 3,4-diaminobenzoic acid derivatives as inhibitors of this class of enzymes, achieving submicromolar inhibitors for ERAP2 (IC50 = 237 nM) and IRAP (IC50 = 105 nM). Cell-based analysis indicated that the lead compounds can be effective in downregulating macrophage activation induced by lipopolysaccharide and interferon-gamma as well as cross-presentation by bone marrow-derived dendritic cells. Our results indicate that this class of inhibitors may be useful for the targeted downregulation of immune responses.

  DOI：

  10.1021/jm501867s

文献信息

• [EN] INHIBITORS OF ALDOSE REDUCTASE<br/>[FR] INHIBITEURS DE L'ALDOSE RÉDUCTASE
  申请人：APPLIED THERAPEUTICS INC

  公开号：WO2020205846A1

  公开（公告）日：2020-10-08

  The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, cardiomyopathy, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, galactosemia, asthma, PMM2-CDG and the like.

  本公开涉及新颖化合物及其药物组合物，以及促进皮肤健康老化、治疗皮肤疾病、心血管疾病、肾脏疾病、血管生成障碍（如癌症）、组织损伤治疗（如非心脏组织损伤）、心肌梗死演变治疗、缺血性损伤治疗以及利用本发明的化合物和组合物治疗糖尿病引起的并发症等方法。其他疾病可能包括但不限于动脉粥样硬化、心肌病、冠状动脉疾病、糖尿病肾病、糖尿病神经病变、糖尿病视网膜病变、糖尿病心肌病、皮肤感染、外周血管疾病、中风、半乳糖血症、哮喘、PMM2-CDG等。
• Synthesis of Novel Modified Guanidines: Reaction of Dicyandiamide with Amino Acids, Amides, and Amines in Aqueous Medium
  作者：Ahmed M. Soliman、Shaaban K. Mohamed、Mahmoud. Abd El Aleem. Ali. Ali. El-Remaily、H. Abdel-Ghany

  DOI：10.1002/jhet.1762

  日期：2014.9

  Reaction of dicyandiamide with series of amino acids afforded guanidinyl pyrazolones 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, respectively. Although reaction of dicyandiamide with urea, acetamide, bezamide, allantion, p‐aminobenzoic acid, sulphanilic acid, and adenine gave biguanides 20, 21, 22, 23, 24, 25, 26, respectively. All compounds have been characterized on the basis

  具有串联的双氰胺反应氨基酸，得到吡唑啉胍2，3，4，5，6，7，8，9，10，11，12，13，14，15，16，17，18，19，分别。虽然与脲，乙酰胺，bezamide，尿囊素，双氰胺的反应p氨基苯甲酸，对氨基苯磺酸，和腺嘌呤给双胍类20，21，22，23，24，25，26，分别。所有化合物均已根据IR和1 H-NMR进行了表征。
• 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES
  申请人：KIM IN JONG

  公开号：US20090075915A1

  公开（公告）日：2009-03-19

  The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

  本发明揭示了以下化合物的化学式I，或其药学上可接受的盐、酯或前药：这些化合物具有抗菌性能。本发明还涉及包含上述化合物的药物组合物，用于治疗需要抗生素治疗的患者。该发明还涉及通过给予含有本发明化合物的药物组合物来治疗患者的细菌感染的方法。该发明还包括制备本发明化合物的方法。
• Hemiasterlin Derivative Having Cysteine Residue
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：US20220144889A1

  公开（公告）日：2022-05-12

  A compound represented by formula (1): wherein b represents an integer of 1 to 5; X represents —NH— or —CO—; Z represents a group represented, for example, by formula (Z-1); R 1 represents a hydrogen atom or (AB) m ; AB represents a particular amino acid residue, and when there is a plurality of ABs, each AB may be the same as or different from each other and ABs are bonded to each other via an amide bond; m represents an integer of 1 to 9; R 2 represents a hydroxy group or (AC) g ; AC represents a particular amino acid residue, and when there is a plurality of ACs, each AC may be the same as or different from each other and ACs are bonded to each other via an amide bond; and g represents an integer of 1 to 9, or a salt thereof.

  化合物的化学式为（1）：其中b表示1至5的整数；X表示—NH—或—CO—；Z表示由化学式（Z-1）表示的基团；R1表示氢原子或(AB)m；AB表示特定的氨基酸残基，当存在多个AB时，每个AB可以相同或不同，并且AB通过酰胺键相互连接；m表示1至9的整数；R2表示羟基或(AC)g；AC表示特定的氨基酸残基，当存在多个AC时，每个AC可以相同或不同，并且AC通过酰胺键相互连接；g表示1至9的整数；或其盐。
• New binder-drug conjugates (ADCs) and use thereof
  申请人：Bayer Pharma AG

  公开号：US20130095123A1

  公开（公告）日：2013-04-18

  The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.

  本申请涉及新的结合剂-药物共轭物（ADCs），其为N，N-二烷基月桂酰基蛋白酶抑制剂，针对C4.4a靶标，以及这些ADCs的活性代谢物，制备这些ADCs的方法，使用这些ADCs治疗和/或预防疾病，以及使用这些ADCs制备治疗和/或预防疾病的药物，更具体地说是治疗和/或预防增生和/或血管生成性疾病，例如癌症。这种治疗可以作为单一疗法，也可以与其他药物或进一步的治疗措施结合使用。